Literature DB >> 15304627

Anticonvulsant hypersensitivity syndrome: lymphocyte toxicity assay for the confirmation of diagnosis and risk assessment.

Sandeep B Bavdekar1, Mamta N Muranjan, Nithya J Gogtay, Vishakha Kantharia, Nilima A Kshirsagar.   

Abstract

OBJECTIVE: To report a case of anticonvulsant hypersensitivity syndrome (AHS) precipitated by exposure to phenobarbital. CASE
SUMMARY: An 11-year-old girl receiving phenobarbital developed fever, exfoliative skin rash, mucous membrane lesions, alopecia, and hepatic inflammation. Investigations ruled out an infectious etiology; an adverse event following phenobarbital administration was considered. Applying the Naranjo probability scale for objective causality assessment showed the adverse reaction was probably due to phenobarbital. The diagnosis was confirmed by in vitro lymphocyte toxicity assay, which demonstrated increased cell death following exposure to phenobarbital, as well as other aromatic anticonvulsants and lamotrigine. DISCUSSION: AHS is a rare, potentially fatal event with multisystem manifestations. It is reported following exposure to aromatic antiepileptics. The mechanism proposed for AHS is accumulation of toxic arene oxide metabolites due to a defect in epoxide hydrolase-mediated detoxification. Despite the difference in chemical structure of lamotrigine, in vitro susceptibility to AHS was demonstrated in our patient.
CONCLUSIONS: Although AHS is a rare event, it should be suspected in patients who develop unexplained systemic manifestations following exposure to aromatic antiepileptics. The potential of lamotrigine to cause AHS should be remembered when this drug is used in subjects who have developed AHS on exposure to phenobarbital and other first-line antiepileptic agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15304627     DOI: 10.1345/aph.1E042

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  10 in total

1.  Interstitial pneumonitis during lamotrigine therapy.

Authors:  Narayanamoorti Saravanan; Olayiwala Musibay Otaiku; Robert Namushi Namushi
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

2.  Probable Anticonvulsant Hypersensitivity Syndrome Due to Fosphenytoin in a Pediatric Patient with Streptococcus pneumoniae Meningitis.

Authors:  Nancy J Gadd
Journal:  J Pediatr Pharmacol Ther       Date:  2007-10

3.  Leukemoid reaction secondary to hypersensitivity syndrome to phenobarbital: a case report.

Authors:  Qinghai Zeng; Yuanqiang Wu; Yi Zhan; Ling Tang; Yangmei Zhou; Jun Yin; Fan Fan; Guiying Zhang; Qianjin Lu; Rong Xiao
Journal:  Int J Clin Exp Pathol       Date:  2012-11-20

4.  Anticonvulsant hypersensitivity syndrome closely mimicking Kawasaki disease.

Authors:  Elpis Mantadakis; Aggelos Tsalkidis; Emmanouel Paraskakis; Kyriaki Papadopoulou-Legbelou; George Varlamis; Athanassios Evangeliou; Athanassios Chatzimichael
Journal:  BMJ Case Rep       Date:  2009-05-25

5.  Type 1 diabetes mellitus in a child with phenobarbital hypersensitivity syndrome.

Authors:  C C Zou; L Liang; J F Fu
Journal:  J Endocrinol Invest       Date:  2008-04       Impact factor: 4.256

Review 6.  In vitro testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review.

Authors:  Abdelbaset A Elzagallaai; Sandra R Knowles; Michael J Rieder; John R Bend; Neil H Shear; Gideon Koren
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 7.  Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review.

Authors:  Abdelbaset A Elzagallaai; Sandra R Knowles; Michael J Rieder; John R Bend; Neil H Shear; Gideon Koren
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 8.  No population left behind: Improving paediatric drug safety using informatics and systems biology.

Authors:  Nicholas P Giangreco; Jonathan E Elias; Nicholas P Tatonetti
Journal:  Br J Clin Pharmacol       Date:  2021-01-19       Impact factor: 3.716

9.  Hepatoprotective and antioxidant activity of N-acetyl cysteine in carbamazepine-administered rats.

Authors:  Eswaran Maheswari; Ganesan Raja Lekshmi Saraswathy; Thakur Santhranii
Journal:  Indian J Pharmacol       Date:  2014 Mar-Apr       Impact factor: 1.200

10.  Cutaneous Adverse Drug Reactions in Dogs Treated with Antiepileptic Drugs.

Authors:  Tina Koch; Ralf S Mueller; Britta Dobenecker; Andrea Fischer
Journal:  Front Vet Sci       Date:  2016-04-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.